8-K: FOXO Technologies Completes Debt-for-Equity Swap, Appoints New CEO, and Aims for NYSE American Compliance

FOXO Technologies has completed a series of transactions, including a debt-for-equity swap, to improve its balance sheet and meet NYSE American listing requirements, while also appointing Seamus Lagan as the new CEO.

Summary

• FOXO Technologies has executed a restructuring involving the exchange of debt and liabilities for equity securities.
• This move is intended to address non-compliance issues with NYSE American listing standards related to minimum stockholders' equity.
• The company has reduced liabilities and increased stockholders' equity by $26.4 million through these transactions.
• Rennova Health, Inc. exchanged approximately $21 million of debt for 21,000 shares of Series A Preferred Stock.
• An institutional investor provided an additional $1 million and exchanged $2.2 million of debt for 2,464 shares of Series A Preferred Stock.
• Liabilities to KR8, Inc. were settled, and a license agreement was terminated for 3,000 shares of Series D Preferred Stock.
• Seamus Lagan has been appointed as the new Chief Executive Officer, effective immediately.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the successful debt restructuring, new CEO appointment, and improved balance sheet. However, risks related to compliance and future profitability temper the overall optimism.

Positives

• The debt-for-equity swap significantly improves the company's balance sheet.
• The company is now in a better position to meet NYSE American listing requirements.
• The appointment of Seamus Lagan as CEO brings experienced leadership to the company.
• The reduction in liabilities and increase in equity is expected to eliminate the risk of delisting.
• The company is positioned for growth in 2025 with reduced liabilities and new revenue generating businesses.

Risks

• The company requires an official notice of compliance from NYSE American to confirm compliance.
• There is a risk that the plan will not be accepted by NYSE American.
• The company may be unable to satisfy other continued listing requirements of NYSE American.
• The company operates in competitive and highly regulated industries.
• There is a risk of changes in laws and regulations affecting FOXO's business.
• The company has a history of losses and may not achieve or maintain profitability in the future.
• There is a risk of downturns and a changing regulatory landscape in the biotechnology industry.

Future Outlook

The company is positioned for growth in 2025 and beyond with a stronger balance sheet and new revenue generating businesses. The company is confident that the improved balance sheet will meet the minimum requirements of the NYSE American.

Management Comments

• Seamus Lagan stated he is excited to work closely with and build operating teams to drive improved performance and shareholder value.
• Seamus Lagan commented that the improved balance sheet will meet the minimum requirements of the NYSE American, eliminating the risk of delisting.

Industry Context

The restructuring and capital raising transactions are aimed at addressing financial challenges and maintaining the company's listing on the NYSE American, which is a common concern for companies in the biotechnology and healthcare sectors. The appointment of a new CEO is also a common strategy for companies seeking to improve performance and investor confidence.

Comparison to Industry Standards

• Many small-cap biotechnology and healthcare companies face challenges in maintaining compliance with exchange listing requirements, similar to FOXO's situation.
• Debt-for-equity swaps are a common strategy for companies with high debt levels to improve their balance sheets, as seen in other companies in similar situations.
• The appointment of a new CEO with experience in distressed companies and capital raising is a common move for companies seeking to turn around their performance, similar to other companies in the sector.
• The specific details of the debt exchange, such as the conversion rates and the types of preferred stock issued, would need to be compared to similar transactions in the industry to assess the fairness and effectiveness of the deal.

Management Changes

Related Party Transactions

• Rennova Health, Inc., a related party, exchanged approximately $21 million of debt for equity.

Stakeholder Impact

• Shareholders should benefit from the improved balance sheet and reduced risk of delisting.
• Employees may experience changes under the new leadership.
• Customers and suppliers may see improved stability and growth potential.
• Creditors have been impacted by the debt-for-equity swap.

Next Steps

• The company will seek an official notice of compliance from NYSE American.
• The company will focus on driving improved performance and shareholder value under the new CEO.
• The company will continue to develop its biotechnology and healthcare businesses.

Key Dates

Keywords

debt-for-equity swap, restructuring, capital raising, NYSE American, Seamus Lagan, CEO, stockholders equity, delisting, compliance, preferred stock